Beyond BMI: The "Metabolically healthy obese" phenotype & its association with clinical/subclinical cardiovascular disease and all-cause mortality -- a systematic review

Lara L Roberson, Ehimen C Aneni, Wasim Maziak, Arthur Agatston, Theodore Feldman, Maribeth Rouseff, Thinh Tran, Michael J Blaha, Raul D Santos, Andrei Sposito, Mouaz H Al-Mallah, Ron Blankstein, Matthew J Budoff, Khurram Nasir, Lara L Roberson, Ehimen C Aneni, Wasim Maziak, Arthur Agatston, Theodore Feldman, Maribeth Rouseff, Thinh Tran, Michael J Blaha, Raul D Santos, Andrei Sposito, Mouaz H Al-Mallah, Ron Blankstein, Matthew J Budoff, Khurram Nasir

Abstract

Background: A subgroup has emerged within the obese that do not display the typical metabolic disorders associated with obesity and are hypothesized to have lower risk of complications. The purpose of this review was to analyze the literature which has examined the burden of cardiovascular disease (CVD) and all-cause mortality in the metabolically healthy obese (MHO) population.

Methods: Pubmed, Cochrane Library, and Web of Science were searched from their inception until December 2012. Studies were included which clearly defined the MHO group (using either insulin sensitivity and/or components of metabolic syndrome AND obesity) and its association with either all cause mortality, CVD mortality, incident CVD, and/or subclinical CVD.

Results: A total of 20 studies were identified; 15 cohort and 5 cross-sectional. Eight studies used the NCEP Adult Treatment Panel III definition of metabolic syndrome to define "metabolically healthy", while another nine used insulin resistance. Seven studies assessed all-cause mortality, seven assessed CVD mortality, and nine assessed incident CVD. MHO was found to be significantly associated with all-cause mortality in two studies (30%), CVD mortality in one study (14%), and incident CVD in three studies (33%). Of the six studies which examined subclinical disease, four (67%) showed significantly higher mean common carotid artery intima media thickness (CCA-IMT), coronary artery calcium (CAC), or other subclinical CVD markers in the MHO as compared to their MHNW counterparts.

Conclusions: MHO is an important, emerging phenotype with a CVD risk between healthy, normal weight and unhealthy, obese individuals. Successful work towards a universally accepted definition of MHO would improve (and simplify) future studies and aid inter-study comparisons. Usefulness of a definition inclusive of insulin sensitivity and stricter criteria for metabolic syndrome components as well as the potential addition of markers of fatty liver and inflammation should be explored. Clinicians should be hesitant to reassure patients that the metabolically benign phenotype is safe, as increased risk cardiovascular disease and death have been shown.

Figures

Figure 1
Figure 1
Search flow chart.

References

    1. World Health Statistics 2012. World Health Organization. 20 Avenue Appia, 1211 Geneva 27, Switzerland: WHO Press; 2012. Retrieved February 12, 2013 from
    1. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity in the United States, 2009–2010. NCHS data brief. 2012;82:1–8.
    1. Solomon CG, Manson JE. Obesity and mortality: a review of the epidemiologic data. Am J Clin Nutr. 1997;66(4 Suppl):1044S–1050S.
    1. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309(1):71–82. doi: 10.1001/jama.2012.113905.
    1. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff (Millwood) 2009;28(5):w822–w831. doi: 10.1377/hlthaff.28.5.w822.
    1. Bluher M. The distinction of metabolically 'healthy' from 'unhealthy' obese individuals. Curr Opin Lipidol. 2010;21(1):38–43. doi: 10.1097/MOL.0b013e3283346ccc.
    1. Karelis AD. To be obese–does it matter if you are metabolically healthy? Nat Rev Endocrinol. 2011;7(12):699–700. doi: 10.1038/nrendo.2011.181.
    1. Wildman RP, Muntner P, Reynolds K. et al.The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: Prevalence and correlates of 2 phenotypes among the us population (nhanes 1999–2004) Arch Intern Med. 2008;168(15):1617–1624. doi: 10.1001/archinte.168.15.1617.
    1. Arnlov J, Ingelsson E, Sundstrom J, Lind L. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation. 2010;121(2):230–236. doi: 10.1161/CIRCULATIONAHA.109.887521.
    1. Calori G, Lattuada G, Piemonti L, Garancini MP, Ragogna F, Villa M, Mannino S, Crosignani P, Bosi E, Luzi L. et al.Prevalence, metabolic features, and prognosis of metabolically healthy obese Italian individuals: the Cremona Study. Diabetes Care. 2011;34(1):210–215. doi: 10.2337/dc10-0665.
    1. Hamer M, Stamatakis E. Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. J Clin Endocrinol Metab. 2012;97(7):2482–2488. doi: 10.1210/jc.2011-3475.
    1. Hosseinpanah F, Barzin M, Sheikholeslami F, Azizi F. Effect of different obesity phenotypes on cardiovascular events in Tehran Lipid and Glucose Study (TLGS) Am J Cardiol. 2011;107(3):412–416. doi: 10.1016/j.amjcard.2010.09.034.
    1. Kuk JL, Ardern CI. Are metabolically normal but obese individuals at lower risk for all-cause mortality? Diabetes Care. 2009;32(12):2297–2299. doi: 10.2337/dc09-0574.
    1. Meigs JB, Wilson PW, Fox CS, Vasan RS, Nathan DM, Sullivan LM, D'Agostino RB. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab. 2006;91(8):2906–2912. doi: 10.1210/jc.2006-0594.
    1. Ogorodnikova AD, Kim M, McGinn AP, Muntner P, Khan U, Wildman RP. Incident cardiovascular disease events in metabolically benign obese individuals. Obesity (Silver Spring) 2012;20(3):651–659. doi: 10.1038/oby.2011.243.
    1. Ortega FB, Lee DC, Katzmarzyk PT, Ruiz JR, Sui X, Church TS, Blair SN. The intriguing metabolically healthy but obese phenotype: cardiovascular prognosis and role of fitness. Eur Heart J. 2013;34(5):389–397. doi: 10.1093/eurheartj/ehs174.
    1. St-Pierre AC, Cantin B, Mauriege P, Bergeron J, Dagenais GR, Despres JP, Lamarche B. Insulin resistance syndrome, body mass index and the risk of ischemic heart disease. CMAJ. 2005;172(10):1301–1305. doi: 10.1503/cmaj.1040834.
    1. Voulgari C, Tentolouris N, Dilaveris P, Tousoulis D, Katsilambros N, Stefanadis C. Increased heart failure risk in normal-weight people with metabolic syndrome compared with metabolically healthy obese individuals. J Am Coll Cardiol. 2011;58(13):1343–1350. doi: 10.1016/j.jacc.2011.04.047.
    1. Katzmarzyk PT, Church TS, Janssen I, Ross R, Blair SN. Metabolic syndrome, obesity, and mortality: impact of cardiorespiratory fitness. Diabetes Care. 2005;28(2):391–397. doi: 10.2337/diacare.28.2.391.
    1. Daly CA, Hildebrandt P, Bertrand M, Ferrari R, Remme W, Simoons M, Fox KM. Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: data from the EUROPA trial. Heart. 2007;93(11):1406–1411. doi: 10.1136/hrt.2006.113084.
    1. Song Y, Manson JE, Meigs JB, Ridker PM, Buring JE, Liu S. Comparison of usefulness of body mass index versus metabolic risk factors in predicting 10-year risk of cardiovascular events in women. Am J Cardiol. 2007;100(11):1654–1658. doi: 10.1016/j.amjcard.2007.06.073.
    1. Bo S, Musso G, Gambino R, Villois P, Gentile L, Durazzo M, Cavallo-Perin P, Cassader M. Prognostic implications for insulin-sensitive and insulin-resistant normal-weight and obese individuals from a population-based cohort. Am J Clin Nutr. 2012;96(5):962–969. doi: 10.3945/ajcn.112.040006.
    1. Bobbioni-Harsch E, Pataky Z, Makoundou V, Laville M, Disse E, Anderwald C, Konrad T, Golay A. From metabolic normality to cardiometabolic risk factors in subjects with obesity. Obesity (Silver Spring) 2012;20(10):2063–2069. doi: 10.1038/oby.2012.69.
    1. Alam I, Ng TP, Larbi A. Does inflammation determine whether obesity is metabolically healthy or unhealthy? Aging Perspect Mediat Inflamm. 2012;2012:14.
    1. Marini MA, Succurro E, Frontoni S, Hribal ML, Andreozzi F, Lauro R, Perticone F, Sesti G. Metabolically healthy but obese women have an intermediate cardiovascular risk profile between healthy nonobese women and obese insulin-resistant women. Diabetes Care. 2007;30(8):2145–2147. doi: 10.2337/dc07-0419.
    1. Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K, Balletshofer B, Machicao F, Fritsche A, Haring HU. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008;168(15):1609–1616. doi: 10.1001/archinte.168.15.1609.
    1. Khan UI, Wang D, Thurston RC, Sowers M, Sutton-Tyrrell K, Matthews KA, Barinas-Mitchell E, Wildman RP. Burden of subclinical cardiovascular disease in "metabolically benign" and "at-risk" overweight and obese women: the Study of Women's Health Across the Nation (SWAN) Atherosclerosis. 2011;217(1):179–186. doi: 10.1016/j.atherosclerosis.2011.01.007.
    1. Park J, Kim SH, Cho GY, Baik I, Kim NH, Lim HE, Kim EJ, Park CG, Lim SY, Kim YH. et al.Obesity phenotype and cardiovascular changes. J Hypertens. 2011;29(9):1765–1772. doi: 10.1097/HJH.0b013e32834a50f3.
    1. Irace C, Scavelli F, Carallo C, Serra R, Cortese C, Gnasso A. Body mass index, metabolic syndrome and carotid atherosclerosis. Coron Artery Dis. 2009;20(2):94–99. doi: 10.1097/MCA.0b013e3283219e76.
    1. Sims EA. Are there persons who are obese, but metabolically healthy? Metabolism. 2001;50(12):1499–1504. doi: 10.1053/meta.2001.27213.
    1. Lebovitz HE, Banerji MA. Point: visceral adiposity is causally related to insulin resistance. Diabetes Care. 2005;28(9):2322–2325. doi: 10.2337/diacare.28.9.2322.
    1. Bonora E, Tuomilehto J. The pros and cons of diagnosing diabetes with A1C. Diabetes Care. 2011;34(Suppl 2):S184–S190.
    1. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 2008;294(1):E15–E26.
    1. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17(1):4–12.
    1. Nordestgaard BG, Zacho J. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander? Nutr Metab Cardiovasc Dis. 2009;19(8):521–524. doi: 10.1016/j.numecd.2009.07.005.
    1. Moore JB. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc. 2010;69(2):211–220. doi: 10.1017/S0029665110000030.
    1. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363(14):1341–1350. doi: 10.1056/NEJMra0912063.
    1. Messier V, Karelis AD, Robillard ME, Bellefeuille P, Brochu M, Lavoie JM, Rabasa-Lhoret R. Metabolically healthy but obese individuals: relationship with hepatic enzymes. Metabolism. 2010;59(1):20–24. doi: 10.1016/j.metabol.2009.06.020.
    1. Soverini V, Moscatiello S, Villanova N, Ragni E, Di Domizio S, Marchesini G. Metabolic syndrome and insulin resistance in subjects with morbid obesity. Obes Surg. 2010;20(3):295–301. doi: 10.1007/s11695-009-9999-z.
    1. Romero CX, Romero TE, Shlay JC, Ogden LG, Dabelea D. Changing trends in the prevalence and disparities of obesity and other cardiovascular disease risk factors in three racial/ethnic groups of USA adults. Adv Prev Med. 2012;2012:172423.
    1. Mensah GA, Mokdad AH, Ford ES, Greenlund KJ, Croft JB. State of disparities in cardiovascular health in the United States. Circulation. 2005;111(10):1233–1241. doi: 10.1161/01.CIR.0000158136.76824.04.
    1. Hankinson AL, Daviglus ML, Van Horn L, Chan Q, Brown I, Holmes E, Elliott P, Stamler J. Diet composition and activity level of at risk and metabolically healthy obese American adults. Obesity (Silver Spring) 2012;21(3):637–643.
    1. Gill JM, Malkova D. Physical activity, fitness and cardiovascular disease risk in adults: interactions with insulin resistance and obesity. Clin Sci (Lond) 2006;110(4):409–425. doi: 10.1042/CS20050207.
    1. Wilmot EG, Edwardson CL, Achana FA, Davies MJ, Gorely T, Gray LJ, Khunti K, Yates T, Biddle SJ. Sedentary time in adults and the association with diabetes, cardiovascular disease and death: systematic review and meta-analysis. Diabetologia. 2012;55(11):2895–2905. doi: 10.1007/s00125-012-2677-z.
    1. Nesto RW. Obesity: a major component of the metabolic syndrome. Texas Heart Institute journal / from the Texas Heart Institute of St Luke's Episcopal Hospital, Texas Children's Hospital. 2005;32(3):387–389.
    1. Wang F, Deeney JT, Denis GV. Brd2 Gene disruption causes "metabolically healthy" obesity: epigenetic and chromatin-based mechanisms that uncouple obesity from type 2 diabetes. Vitam Horm. 2013;91:49–75.
    1. Speakman JR. Obesity: the integrated roles of environment and genetics. J Nutr. 2004;134(8 Suppl):2090S–2105S.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj